<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="756">
  <stage>Registered</stage>
  <submitdate>16/09/2005</submitdate>
  <approvaldate>29/09/2005</approvaldate>
  <actrnumber>ACTRN12605000553673</actrnumber>
  <trial_identification>
    <studytitle>Cellular Immune responses to Hepatitis B Virus (HBV)- Longitudinal follow up and Natural History</studytitle>
    <scientifictitle>Cellular Immune responses to Hepatitis B Virus (HBV)- Longitudinal follow up and Natural History</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B infection and Hepatitis B/HIV co-infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>None, this is an observational study 

It remains unclear why some individuals are able to clear HBV from their bodies while in others HBV is a persistent infection. We plan to investigate this process by collecting blood and analysing how the patients white blood cells respond to different pieces of the HBV virus. We will use new tools that can precisely tell us which component of the immune response may be different in individuals who are chronically infected with HBV and also in individuals who are also infected with HIV.</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To characterize HBV-specific T cell responses in HBV chronic carriers</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To identify novel immunogenic regions in both HLA-A2+ and non-HLA-A2+ individuals</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the effect of HIV infection on HBV-specific T-cell responses</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome />
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>There are two groups of patients in this study. Group A mono-infected with Hepatitis B, and those with co-infection HBV/HIV.Group A inclusion criteria: (also split into 6 recruiting groups)1- Acute hepatitis B2- Chronic hepatitis B, HBV DNA+ve , normal ALT , HBeAg +ve3- Chronic hepatitis B, HBV DNA +ve , normal ALT, HBeAg -ve4- Chronic hepatitis , HBV DNA +ve, increased ALT, no HBV treatment B, HBeAg +ve5- Chronic hepatitis B, HBV DNA +ve , increased ALT, no HBV treatment B, HBeAg -ve6- Chronic hepatitis B, undergoing 'flare' of hepatitis. Group B inclusion criteria:to be HIV/HBV co-infected.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>5/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>104</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NIH</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NIH</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress>Commercial Road, Melbourne Victoria 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Royal Melbourne Hospital</ethicname>
      <ethicaddress>Flemngton Road, Melbourne, Victoria</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Sharon Lewin</name>
      <address>Infectious Diseases Department
Alfred Hospital
2nd floor
Burnet Institute
Commercial Rd
Melbourne VIC 3004</address>
      <phone>+61 3 92763009</phone>
      <fax>+61 3 92762431</fax>
      <email>S.Lewin@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Sharon Lewin</name>
      <address>Infectious Diseases Department
Alfred Hospital
2nd floor
Burnet Institute
Commercial Rd
Melbourne VIC 3004</address>
      <phone>+61 3 92763009</phone>
      <fax>+61 3 92762431</fax>
      <email>S.Lewin@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>